We are live on ! Find out more
KYTX icon

Kyverna Therapeutics

99 hedge funds and large institutions have $321M invested in Kyverna Therapeutics in 2025 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 9

135% more capital invested

Capital invested by funds: $136M → $321M (+$184M)

100% more funds holding in top 10

Funds holding in top 10: 36 (+3)

38% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 21

32% more funds holding

Funds holding: 7599 (+24)

25.45% more ownership

Funds ownership: 52.48%77.93% (+25%)

19% less call options, than puts

Call options by funds: $967K | Put options by funds: $1.19M

Holders
99
Holders Change
+24
Holders Change %
+32%
% of All Funds
1.2%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.07%
New
36
Increased
29
Reduced
21
Closed
9
Calls
$967K
Puts
$1.19M
Net Calls
-$227K
Net Calls Change
-$1.29M

KYTX Hedge Fund Activity: Q4 2025 in Review

99 of the 8,275 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q4 2025, worth a combined $321M — up 135% from $136M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new KYTX positions and 9 closed out — a net gain of 27 holders — while 29 added to existing stakes and 21 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $14.8M. The largest seller was Franklin Resources, exiting entirely with an estimated $4.07M sold.

  • 99 institutional investors held Kyverna Therapeutics (KYTX) as of Q4 2025, up from 75 in Q3 2025.
  • Funds reported $321M of Kyverna Therapeutics stock for Q4 2025, up 135% quarter-over-quarter.
  • 36 funds opened new Kyverna Therapeutics positions in Q4 2025 and 9 closed out, a net change of +27 holders.
  • The largest Kyverna Therapeutics buyer in Q4 2025 was Deerfield Management, an estimated $14.8M added.
  • The largest Kyverna Therapeutics seller in Q4 2025 was Franklin Resources, an estimated $4.07M sold.

Based on aggregated 13F filings for Q4 2025.